Related references
Note: Only part of the references are listed.A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer
Michael A. Morse et al.
ANNALS OF SURGERY (2013)
Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells
Yasumitsu Uchida et al.
CANCER BIOLOGY & THERAPY (2013)
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Ravi A. Madan et al.
LANCET ONCOLOGY (2012)
MUC1c Regulates Cell Survival in Pancreatic Cancer by Preventing Lysosomal Permeabilization
Sulagna Banerjee et al.
PLOS ONE (2012)
MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells
Hasan Rajabi et al.
PROSTATE (2012)
MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells
Li Yin et al.
BLOOD (2011)
A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
Mahsa Mohebtash et al.
CLINICAL CANCER RESEARCH (2011)
Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial
Charles Butts et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition
L. D. Roy et al.
ONCOGENE (2011)
MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients
Dhara M. MacDermed et al.
BMC MEDICAL GENOMICS (2010)
MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells
E. Lacunza et al.
CANCER GENETICS AND CYTOGENETICS (2010)
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy
Vittore Cereda et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Vaccine against MUC1 Antigen Expressed in Inflammatory Bowel Disease and Cancer Lessens Colonic Inflammation and Prevents Progression to Colitis-Associated Colon Cancer
Pamela L. Beatty et al.
CANCER PREVENTION RESEARCH (2010)
Survival of Human Multiple Myeloma Cells Is Dependent on MUC1 C-Terminal Transmembrane Subunit Oncoprotein Function
Li Yin et al.
MOLECULAR PHARMACOLOGY (2010)
Oncogenic function of the MUC1 receptor subunit in gene regulation
D. Kufe
ONCOGENE (2010)
MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells
Shawn P. Fessler et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Functional targeting of the MUC1 oncogene in human cancers
Donald W. Kufe
CANCER BIOLOGY & THERAPY (2009)
MUC1-Induced Transcriptional Programs Associated with Tumorigenesis Predict Outcome in Breast and Lung Cancer
Nikolai N. Khodarev et al.
CANCER RESEARCH (2009)
Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells
Deepak Raina et al.
CANCER RESEARCH (2009)
MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment
Sean P. Pitroda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Mucins in cancer: function, prognosis and therapy
Donald W. Kufe
NATURE REVIEWS CANCER (2009)
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
James L. Gulley et al.
CLINICAL CANCER RESEARCH (2008)
A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer
Rodryg Ramlau et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells
Takeshi Kawano et al.
CANCER RESEARCH (2007)
The cytotoxic T cell response to peptide analogs of the HLA-A*0201-restricted MUC1 signal sequence epitope, M1.2
Malcolm S. Mitchell et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene
Xiaolong Wei et al.
CANCER RESEARCH (2007)
MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma
Xiu Feng Hu et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
Multiple costimulatory modalities enhance CTL avidity
JW Hodge et al.
JOURNAL OF IMMUNOLOGY (2005)
Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer
RK Ramanathan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1
KY Tsang et al.
CLINICAL CANCER RESEARCH (2004)
Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents
J Ren et al.
CANCER CELL (2004)
Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1)
KG Kohlgraf et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Mucins in cancer: Protection and control of the cell surface
MA Hollingsworth et al.
NATURE REVIEWS CANCER (2004)
Human DF3/MUC1 carcinoma-associated protein functions as an oncogene
YQ Li et al.
ONCOGENE (2003)
Segregation of receptor and ligand regulates activation of epithelial growth factor receptor
PD Vermeer et al.
NATURE (2003)
Selective induction of high avidity CTL by altering the balance of signals from APC
S Oh et al.
JOURNAL OF IMMUNOLOGY (2003)
MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses
ML VanLith et al.
INTERNATIONAL IMMUNOLOGY (2002)
Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines
CL Sivinski et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and β-catenin
YQ Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL
MA Derby et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
